Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFIRI + aflibercept in metastatic colorectal cancer with or without ACE polymorphisms
2016-001508-45Phase 2Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Jul 2016
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of aflibercept, irinotecan, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-free survival. Started Jul 2016; status: completed.
02
Drugs
afliberceptirinotecanfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2016-001508-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001508-45.